U.S. Consumer Durables Stock News

QuidelOrtho (QDEL) has come under pressure after several reports highlighted a sharp share price drop, with investors focusing on worsening profitability, declining margins, and an Altman Z-Score that flags elevated financial distress risk. See our latest analysis for QuidelOrtho. That recent double digit slide in QuidelOrtho’s share price sits against a more mixed backdrop, with a 7 day share price return of 13.62% decline, a year to date share price return of 6.18%, and a 1 year total...

Commerce Bancshares (CBSH) closed out FY 2025 with fourth quarter revenue of US$436.3 million and basic EPS of US$1.01, set against a trailing twelve month revenue base of US$1.71 billion and EPS of US$4.04 that frames the full year picture. Over recent periods, the company has seen quarterly revenue move from US$409.6 million in Q4 2024 to US$436.3 million in Q4 2025, while basic EPS has gone from US$0.95 to US$1.01. This gives investors a clearer view of how the top and bottom lines are...

If you are wondering whether Vicor at around US$166.78 is priced for perfection or still offers value, you are not alone. The stock has posted returns of 14.6% over the last 7 days, 53.1% over 30 days, 42.7% year to date, 189.3% over 1 year, 137.2% over 3 years, and 86.1% over 5 years, which naturally raises questions about what is already reflected in the price. Recent attention on Vicor has been shaped by ongoing interest in power electronics and semiconductor related names, as investors...

In recent months, CNX Resources has attracted mixed analyst reactions as rising natural gas prices and consistent operational execution drew both optimism and caution. At the same time, CNX’s Radical Transparency environmental data initiative and ongoing capital return program have become central to how investors interpret its long-term operating profile. With these developments in mind, we’ll examine how CNX’s stronger free cash flow profile and disciplined share repurchases shape its...

Recently, Figma drew attention as financial institutions executed a cluster of unusual options trades across a US$15 to US$45 strike range, alongside split sentiment in options positioning. This surge in complex derivatives activity, paired with differing analyst views, hints that professional investors are actively reassessing Figma’s near-term risk and reward balance. Next, we’ll examine how this unusual options activity shapes Figma’s investment narrative and what it may signal for...

If you are wondering whether Eastern Bankshares at US$20.36 still offers value, the key question is how its current price lines up with its fundamentals. The stock has recorded returns of 4.1% over the last 7 days, 8.6% over 30 days, 9.8% year to date, 19.2% over 1 year, 26.9% over 3 years and 43.6% over 5 years, which naturally raises questions about what is already priced in and what might still be on the table. Recent attention on Eastern Bankshares has centered on its position in the...

CrowdStrike Holdings (CRWD) is back in focus after announcing new regional cloud infrastructure in Saudi Arabia, India, and the United Arab Emirates. This move is tied to rising data residency requirements and demand in regulated markets. See our latest analysis for CrowdStrike Holdings. That push into new regional clouds comes as the share price has been choppy, with a 1 day share price return of 1.77% but a 90 day share price return decline of 13.95%, while the 3 year total shareholder...

In recent weeks, CVS Health has come under increased scrutiny from the US House Judiciary Committee over alleged anticompetitive practices in its pharmacy benefit manager operations, raising questions about how it manages relationships with digital and independent pharmacies. This focus on CVS Health’s internal documents and business conduct is material because it could shape future regulatory approaches to vertically integrated healthcare companies and their pricing power. With regulatory...

Why Genpact (G) may be on investors’ radar today Genpact (G) is drawing attention after recent share price moves, with the stock closing at $46.19 and showing mixed short term returns alongside moderate gains over the past 3 months and year. See our latest analysis for Genpact. The recent 1 day share price return of 1.01% comes after a softer 1 month share price return of 4.03%. At the same time, the 90 day share price return of 16.97% and 1 year total shareholder return of 1.55% suggest...

Morgan Stanley (MS) is back in focus after fourth quarter earnings beat expectations, with wealth management and institutional securities driving the result, and a 6% share price jump underscoring renewed investor attention. See our latest analysis for Morgan Stanley. Those results sit against a share price of $183.05, with a 90 day share price return of 11.71% and a 1 year total shareholder return of 36.56%. This suggests momentum has been building, while recent earnings, capital returns and...

If you are wondering whether Amazon.com is truly good value at today’s price, you are not alone. This article will walk through the key numbers that matter. With the share price at US$234.34, Amazon.com has seen a 1.6% decline over the last 7 days, a 0.9% gain over 30 days, a 3.5% gain year to date, and a 0.5% decline over the last year, while the 3 year and 5 year returns sit at 136.2% and 44.8% respectively. These returns sit against an ongoing flow of news around Amazon.com's core e...

In January 2026, Butterfly Network, Inc. issued guidance indicating it expects at least 17% year-over-year revenue growth for the fourth quarter of 2025, prompting fresh attention from the analyst community. This guidance has highlighted the potential of Butterfly Network’s ultrasound platform across multiple business lines, drawing interest from both healthcare-focused and generalist investors. Next, we’ll explore how this outlook for at least 17% revenue growth shapes Butterfly Network’s...

Diversified Energy recently reported very large year-on-year revenue growth from its U.S. natural gas and liquids operations, while continuing to grapple with weak profitability and pressured earnings per share. At the same time, the company’s high dividend yield of 9.41% has drawn fresh investor attention, raising questions about how sustainable such payouts may be given its current earnings profile. Against this backdrop, we’ll examine how the combination of strong revenue growth and an...

Last week, Context Therapeutics Inc. ( NASDAQ:CNTX ) insiders, who had purchased shares in the previous 12 months were...

Dolby Laboratories (DLB) just released quarterly results, with revenue slightly ahead of expectations. However, its outlook for next quarter revenue and EPS came in much softer, creating a fresh focal point for investors. See our latest analysis for Dolby Laboratories. At a share price of $62.69, Dolby’s recent 1-month share price return of 5% and year to date share price return of 1.32% sit against a 1-year total shareholder return decline of 20.64%. This suggests momentum has softened even...

Mine disruption puts Nexa Resources (NEXA) in focus Nexa Resources (NEXA) temporarily halted production at its Atacocha San Gerardo open pit mine after the Joraoniyoc community blocked road access. The company is concentrating operations on essential maintenance with a reduced workforce. See our latest analysis for Nexa Resources. The production halt comes after a sharp run up, with Nexa Resources posting a 38.31% 30 day share price return and a 117.11% 90 day share price return, while its 1...

PACCAR (NasdaqGS:PCAR) announced the retirement of Executive Vice President C. Michael Dozier after 37 years with the company. Dozier’s retirement marks the departure of a long-serving leader involved in PACCAR’s senior management for multiple decades. The transition highlights a change in executive leadership that may be relevant for investors focused on governance and continuity. PACCAR, through brands such as Kenworth, Peterbilt, and DAF, is a major manufacturer in the global commercial...

Wondering if IQVIA Holdings is priced fairly right now, or if there could be value still on the table for you as an investor? IQVIA's share price last closed at US$239.05, with a 7 day return of 0.9% decline, a 30 day return of 6.2%, a year to date return of 6.1%, a 1 year return of 16.0% and a 3 year return of 4.6%, with a 5 year return of 33.8%. Recent news coverage has focused on IQVIA's role as a large player in data, analytics and services for the life sciences sector. This can shape...

Banco Latinoamericano de Comercio Exterior S. A (BLX) recently closed a US$150 million global syndicated loan led by Nexent Bank N.V., drawing ten participating institutions, a funding move that could be important for shareholders. See our latest analysis for Banco Latinoamericano de Comercio Exterior S. A. The stock has picked up some short term momentum, with a 1 month share price return of 7.60% and a year to date gain of 8.22%. The 1 year total shareholder return of 35.31% sits alongside...

If you are wondering whether CNH Industrial's current share price really reflects what the business is worth, you are not alone. This article is here to unpack that question in a clear way. The stock most recently closed at US$11.05, with returns of 2.1% over 7 days and 18.1% over 30 days, while the 1 year and 3 year returns of negative 12.3% and negative 30.9% show a very different picture to the 18.2% year to date gain. These mixed returns have put valuation back in focus for many...

STAAR Surgical (NasdaqGM:STAA) has reconstituted its Board of Directors and appointed Neal C. Bradsher as independent Board Chair. Three new directors have joined the Board, while two existing directors have stepped down. The Board has formed new committees, including a Search Committee to oversee the process of identifying a successor to the current CEO. The current CEO is expected to step down by the end of January 2026, establishing a defined leadership transition timeline. STAAR...

Third Coast Bancshares (TCBX) closed out FY 2025 with fourth quarter revenue of US$54.2 million and EPS of US$1.21, while on a trailing twelve month basis revenue reached US$201.3 million and EPS came in at US$4.45. The company has seen revenue move from US$158.9 million and EPS of US$2.85 on a trailing basis in Q3 2024 to US$201.3 million and EPS of US$4.45 by Q4 2025, alongside trailing net income rising from US$38.9 million to US$61.5 million over the same window. With net profit margins...

If you are wondering whether TG Therapeutics at around US$31.63 is offering fair value or an opportunity, it helps to start by grounding the share price in a clear valuation framework. The stock has returned 3.0% over the last 7 days, 2.9% over the past month, 8.0% year to date and 8.9% over the past year, while the 3 year return of 123.5% sits against a 5 year return of a 34.2% decline. Recent moves sit in the context of ongoing interest in TG Therapeutics and its product portfolio, as...

The SEC is investigating Jefferies Financial Group (NYSE:JEF) for potential securities law violations. The probe focuses on how the firm disclosed its exposure to the collapsed First Brands Group. Jefferies reported a loss tied to First Brands through its Point Bonita fund. The investigation centers on the adequacy and timing of Jefferies' disclosures to investors. Jefferies Financial Group, a diversified financial services company, is closely watched for its investment banking, trading,...